IceCure Medical (NASDAQ:ICCM) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Alliance Global Partners lifted their price objective on IceCure Medical from $1.90 to $2.90 and gave the company a buy rating in a report on Wednesday, March 20th.

IceCure Medical Price Performance

Shares of ICCM opened at $1.23 on Tuesday. The company has a current ratio of 3.66, a quick ratio of 3.08 and a debt-to-equity ratio of 0.03. IceCure Medical has a 1 year low of $0.52 and a 1 year high of $1.57. The stock has a market cap of $56.11 million, a P/E ratio of -3.73 and a beta of 0.73. The stock’s 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.11.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Wednesday, April 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. IceCure Medical had a negative return on equity of 86.96% and a negative net margin of 453.76%. The firm had revenue of $1.26 million for the quarter. During the same quarter last year, the business posted ($0.11) EPS. On average, equities analysts predict that IceCure Medical will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On IceCure Medical

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new stake in IceCure Medical in the 2nd quarter valued at approximately $78,000. UBS Group AG raised its position in IceCure Medical by 1,302.3% in the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after buying an additional 26,919 shares during the last quarter. Bank of America Corp DE raised its position in IceCure Medical by 57.2% in the 4th quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after buying an additional 20,159 shares during the last quarter. Finally, Boothbay Fund Management LLC raised its position in IceCure Medical by 100.0% in the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after buying an additional 20,000 shares during the last quarter. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.